GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Eli Lilly and Co.

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.

Doctors at the University of Utah’s Moran Eye Center have reviewed cases of nine patients who developed vision problems while ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

The case for GLP-1 drugs like Ozempic possibly causing blindness is building. A new paper out this week describes several ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...